chronic renal failure stage 5
Jump to navigation
Jump to search
Management
- ACE inhibitor or ARB delays progression to ESRD but not mortality[3]
- in patients aged > 75 years with high comorbidity, survival advantage conferred by hemodialysis over conservative management is likely to be small[2]
- age > 75 years & female gender predicts better survival in conservatively managed patients
- initiation of dialysis is often associated with a significant functional decline
More general terms
Additional terms
References
- ↑ Da Silva-Gane M, Wellsted D, Greenshields H et al Quality of life and survival in patients with advanced kidney failure managed conservatively or by dialysis. Clin J Am Soc Nephrol. 2012 Dec;7(12):2002-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22956262
- ↑ 2.0 2.1 Chandna SM, Da Silva-Gane M, Marshall C, Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapy. Nephrol Dial Transplant. 2011 May;26(5):1608-14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21098012
- ↑ 3.0 3.1 Ku E, Inker LA, Tighiouart H et al. Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials. Ann Intern Med. 2024. July 2 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38950402 Review. https://www.acpjournals.org/doi/10.7326/M23-3236
- ↑ Centers for Disease Control and Prevention (CDC) Chronic Kidney Disease (CKD) Surveillance Project https://nccd.cdc.gov/ckd/Help.aspx?section=F#3